Cagrilintide Side Effects

Reported Cagrilintide side effects

Cagrilintide's side-effect profile is dominated by gastrointestinal effects similar to but distinct from GLP-1 agonists, with some amylin-specific considerations. Most Common Side Effects (from trials): Gastrointestinal (dose-dependent): Nausea: in the Phase 2 monotherapy trial, roughly 20%-47% across cagrilintide doses vs 18% placebo (overall GI adverse events 41%-63% vs 32% placebo) - generally mild-to-moderate, tends to decrease with continued dosing Vomiting: more common at higher doses; less common than with GLP-1 agonists at equivalent weight loss Diarrhea: moderate frequency Constipation: less common than with semaglutide Decreased appetite: expected and desired effect; can become problematic if excessive Dyspepsia / abdominal discomfort: moderate frequency Early satiety: expected effect, sometimes extreme Metabolic Effects: Fatigue: modest, especially during rapid weight loss Headache: mild-to-moderate, transient Dizziness: especially in dehydrated individuals or with rapid dose escalation Injection site reactions: mild, transient CagriSema-Specific Considerations: When combined with semaglutide, GI tolerability is broadly similar to semaglutide alone in the Phase 1b trial, suggesting the amylin component does not proportionally worsen GI adverse events despite adding a mechanism of action. In the larger Phase 3 REDEFINE trials, GI adverse events were common (about 72-80% with CagriSema vs 34-40% placebo) but mostly transient and mild-to-moderate. Rare Serious Adverse Events: Pancreatitis: theoretical concern with incretin-amylin axis modulation; not clearly elevated in trials but monitoring required Gallbladder disease: elevated risk during rapid weight loss (common with any weight-loss drug) Hypoglycemia: rare with monotherapy in non-diabetic patients; more common when combined with insulin or sulfonylureas in diabetic patients Amylin-Specific Considerations: Amyloidogenicity Concerns: Native amylin is amyloidogenic and forms pancreatic amyloid in type 2 diabetes. Clinical amylin analogs (including cagrilintide) incorporate proline substitutions to prevent amyloid formation. Clinical trials to date have shown no evidence of iatrogenic amyloidosis from cagrilintide, but this remains a theoretical long-term consideration. Calcitonin Receptor Effects: Cagrilintide retains some calcitonin receptor binding, raising theoretical concerns about: Thyroid C-cell effects (as with GLP-1 agonists) Calcium/phosphate homeostasis (calcitonin's native role) Trials to date have not shown clinically meaningful effects in these domains. Thyroid C-Cell Tumors: Like GLP-1 agonists, cagrilintide carries a theoretical concern about medullary thyroid cancer risk based on rodent studies. CagriSema labeling will likely inherit the MTC/MEN2 contraindication from semaglutide. Specific Populations: Pregnancy: Like all weight-loss drugs, cagrilintide is not indicated during pregnancy. Weight loss is contraindicated during pregnancy. Women of reproductive potential should use effective contraception during treatment and discontinue before planned conception. Elderly: Limited data in patients >75 years; may require more careful dose titration given altered pharmacokinetics and increased fall risk with weight loss. Renal Impairment: Not primarily renally cleared, but caution warranted in severe renal impairment until more data accumulates. Hepatic Impairment: Limited data; exercise caution in severe hepatic dysfunction. Children/Adolescents: Not yet studied; pediatric obesity trials may follow adult approval. Red Flags Requiring Discontinuation: Severe persistent nausea/vomiting unresponsive to supportive care Signs of pancreatitis (severe abdominal pain radiating to back) Signs of gallbladder disease (RUQ pain, jaundice) Signs of hypoglycemia requiring rescue (especially in diabetic patients) Psychiatric symptoms: significant mood changes Severe injection site reactions Any sign of thyroid abnormality (neck mass, dysphagia, dyspnea, hoarseness) Long-Term Safety: As a relatively new molecule (albeit with an amylin receptor mechanism dating to pramlintide's 2005 approval), cagrilintide lacks very long-term (5-10+ year) safety data. Post-marketing surveillance will be essential for: Cancer signals (particularly thyroid) Cardiovascular outcomes Psychiatric effects Weight regain trajectory after discontinuation Effects on lean muscle mass Comparison with Other Weight-Loss Drugs: Cagrilintide (and by extension CagriSema) appears to have: Similar overall GI tolerability to semaglutide (not proportionally worse despite dual mechanism) Better than liraglutide for convenience (once weekly vs daily) Less long-term data than liraglutide, semaglutide, or tirzepatide

When to continue, reduce, or stop Cagrilintide

Cagrilintide contraindications

Absolute Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) Multiple endocrine neoplasia type 2 (MEN2) Known hypersensitivity to cagrilintide, semaglutide, or any component Pregnancy (weight loss contraindicated) Active eating disorder (anorexia nervosa, severe bulimia) Severe untreated psychiatric conditions Relative Contraindications (Require Careful Evaluation): History of pancreatitis: not absolute but high caution Severe gastroparesis: may worsen Gallbladder disease: increased risk during rapid weight loss Inflammatory bowel disease: caution with GI effects Severe renal impairment (eGFR <30): limited data Severe hepatic impairment: limited data Age >75: careful titration needed Children/adolescents: not yet studied Drug Interactions: Medications Requiring Adjustment: Insulin: may need 20-40% dose reduction (hypoglycemia risk) Sulfonylureas: consider dose reduction or discontinuation Thyroid replacement: monitor and adjust as weight changes Levothyroxine: absorption may be affected; separate by 30 min+ Oral contraceptives: absorption may be altered; barrier backup recommended Warfarin: monitor INR (altered absorption possible) Medications to Use with Caution: Other GLP-1 agonists: avoid concurrent use (redundant, increased AE) Other amylin analogs (pramlintide): avoid concurrent use Opioids: may worsen constipation Sedatives: may worsen dizziness Lithium: altered clearance possible Medications Compatible: Most antihypertensives Statins Metformin (often beneficial combination) SSRIs (monitor mood changes) Most thyroid medications (with monitoring) Most HRT (estrogen, testosterone) Medical Conditions Requiring Caution: Gastrointestinal: Gastroparesis: worsening risk Inflammatory bowel disease: caution Peptic ulcer disease: monitor History of bowel obstruction: contraindicated Pancreatic: History of pancreatitis: high caution Pancreatic insufficiency: monitor Pancreatic cancer risk: theoretical Thyroid: Medullary thyroid carcinoma (personal or family): contraindicated MEN2 syndrome: contraindicated Benign thyroid nodules: monitor Autoimmune thyroiditis: manage thyroid function separately Gallbladder: Gallstones: increased risk with rapid weight loss Previous cholecystectomy: no additional contraindication Active symptoms: manage before starting Cardiovascular: Recent myocardial infarction: delay start Severe heart failure: monitor Hypertension: typically improves with weight loss Renal: Mild-moderate impairment: no major concerns Severe impairment (eGFR <30): limited data Hemodialysis: not well-studied Hepatic: Non-alcoholic fatty liver: typically improves with weight loss Severe cirrhosis: limited data Alcoholic liver disease: manage separately Psychiatric: Depression: monitor closely (any weight-loss drug can affect mood) Anxiety disorders: monitor History of suicidal ideation: careful monitoring Eating disorders: contraindicated if active Pregnancy/Reproductive: Pregnancy: absolute contraindication Breastfeeding: not well-studied Effective contraception during treatment Pre-conception: discontinue 4-6 weeks before When to Stop Immediately: Anaphylactoid/severe hypersensitivity reaction Severe persistent pancreatitis symptoms Suspected medullary thyroid cancer Severe gallbladder disease Severe psychiatric emergency Pregnancy (discovery or planning) Severe unexplained weight loss When to Consult Physician: Severe or persistent GI symptoms Suspected pancreatitis New thyroid symptoms (neck mass, dysphagia) Gallbladder symptoms Significant mood changes Severe fatigue Unexpected labs Pregnancy plans New medical conditions Pre-Treatment Assessment: Complete medical history Medication reconciliation Baseline labs (complete metabolic panel, lipids, HbA1c, TSH, liver enzymes) Mental health screening Physical exam ECG if cardiovascular concerns Pregnancy test if applicable Patient education on risks/benefits Monitoring Schedule: Baseline: complete evaluation Month 1: clinical visit, symptoms review Month 3: labs + clinical assessment Month 6: labs + body composition + complete reassessment Month 12: annual evaluation Ongoing: symptom tracking, quality of life Integration with Medical Care: CagriSema/cagrilintide use benefits from clinical oversight: Primary care with weight management expertise Endocrinology for complex diabetes or thyroid Bariatric medicine for advanced cases Nutrition counseling Mental health support Solo use is possible but coordination with physicians optimizes outcomes and safety. Insurance coverage often requires specific documentation and monitoring.

Why vendor quality drives Cagrilintide side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Cagrilintide side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .